New York City – – September 29, 2026 -- Demy-Colton has released the agenda for BioFuture 2026, a two-day conference set for October 27–28 at Cure, 345 Park Avenue South, drawing more than 100 speakers and over 50 presenting companies from biopharma, investment, technology and policy sectors.

Las Vegas – September 19, 2026 -- The paroxysmal nocturnal hemoglobinuria (PNH) market across the seven major markets was valued at approximately $1.5 billion in 2025 and is projected to grow at a compound annual growth rate of 7.1% through 2036, according to DelveInsight.

San Francisco – September 10, 2026 -- Hagens Berman Sobol Shapiro LLP has filed a securities class action against Regeneron Pharmaceuticals (NASDAQ: REGN) after the failure of a Phase 3 melanoma trial wiped out $11 billion in market capitalization. The suit covers investors who purchased Regeneron shares between August 1, 2025, and May 15, 2026, with a lead plaintiff deadline set for September 14, 2026.